Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

The stock’s 50 day simple moving average is $15.19 and its two-hundred day simple moving average is $13.17. The firm has a market cap of $24.33 million, a PE ratio of -0.25 and a beta of 0.41. Cara Therapeutics has a fifty-two week low of $8.13 and a fifty-two week high of $31.32.

Institutional Investors Weigh In On Cara Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Curi RMB Capital LLC bought a new position in Cara Therapeutics in the 4th quarter valued at approximately $277,000. Shay Capital LLC acquired a new position in shares of Cara Therapeutics during the fourth quarter worth $524,000. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Cara Therapeutics in the 4th quarter valued at $953,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.